Life4me+-ის ერთ-ერთი მთავარი მიზანია აივ, სხვა სგგი, ჰეპატიტი C და ტუბერკულოზის ახალი შემთხვევების პრევენცია.

აპლიკაცია ეხმარება აივ დადებით პირებს ექიმებთან ანონიმური კომუნიკაციის დამყარებაში. ეს ყველაფერი დაგეხმარებათ ორგანიზება გაუკეთოთ მედიკამენტების მიღების განრიგს და დააყენოთ ფარული და პერსონალიზებული შეხსენებები.


Specialized clinical information about coronavirus COVID-19

The situation is rapidly evolving, and information is being constantly updated. Last updated

View FAQs about COVID-19 and people living with HIV

View FAQs
Coronavirus Innovation Map
Rights in the time of COVID-19. Lessons from HIV for an effective, community-led response.
What People Living with HIV Need to Know about HIV and COVID-19
EACS & BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH) and SARS-CoV-2 vaccine advice for adults living with HIV
SARS-CoV-2 /COVID-19 - Antiviral and immunomodulatory treatment considerations
Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium
Inpatient guidance for treatment of COVID-19 in adults and children (University of Michigan, USA)
Руководство по лечению и поддерживающей терапии пациентов с коронавирусной инфекцией COVID-19 (Италия, Ломбардия)
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) (Released by National Health Commission & State Administration of Traditional Chinese Medicine)
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
“Recovery” clinical trial for COVID-19 treatments
“Solidarity” clinical trial for COVID-19 treatments
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
NIH Final report confirms remdesivir benefits for COVID-19
WHO Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results
Remdesivir for the Treatment of Covid-19 — Final Report
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Increased efficacy with longer inter-dose interval. Protection of over 70% starting after a first dose. First indication of reduction in disease transmission of up to 67%
Sputnik V COVID-19 vaccine candidate appears safe and effective
Johnson & Johnson: Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2
EATG (European Aids Treatment Group) statement on the evolving COVID-19 pandemic
The Position of Correlation-European Harm Reduction Network and EHRA on the Continuity of Harm Reduction Services During the COVID-19 Crisis
Human Rights Dimensions of COVID-19 Response
COVID-19: Sex Workers Need Immediate Financial Support and Protection
COVID19: “Staying Home” Not an Option for People Experiencing Homelessness
Coronavirus: Healthcare and human rights of people in prison

View FAQs about COVID-19 and people living with HIV

View FAQs

If you have questions or comments about HIV and COVID-19, let us know [email protected]